5893-10-7

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Formyl-DL-alanine is utilized as a key intermediate in the synthesis of various pharmaceuticals and organic compounds, contributing to the development of new drugs and therapeutic agents.
Used in Antibacterial and Antifungal Agents:
In the field of medicine, N-Formyl-DL-alanine is employed as a precursor in the development of antibacterial and antifungal agents, leveraging its unique chemical properties to combat infections and improve patient outcomes.
Used in Research and Development:
N-Formyl-DL-alanine is of significant interest to researchers and scientists due to its potential applications in various industries. Ongoing studies and research are being conducted to explore its full potential, further expanding its uses and benefits in different sectors.

InChI:InChI=1/C29H41N3O3/c1-3-5-6-7-11-23-12-14-24(15-13-23)28(33)31-25-16-17-27(32-19-8-9-20-32)26(22-25)29(34)30-18-10-21-35-4-2/h12-17,22H,3-11,18-21H2,1-2H3,(H,30,34)(H,31,33)

Upstream product

• 64-18-6 formic acid 
• 302-72-7 rac-Ala-OH 
• 2258-42-6 formyl acetic anhydride 
• 328-42-7 Oxalacetic acid 
• 127-17-3 2-oxo-propionic acid 
• 56-41-7 L-alanin 
• 113388-44-6 (formyloxy)(acetoxy)phenylmethane 
• 13549-49-0 2-(formamido)acrylic acid 
• 109-94-4 formic acid ethyl ester 
• 222845-01-4 N-formylalanine phenyl ester 

Downstream Products

• 21709-64-8 3-formylamino-butan-2-one 
• 19561-23-0 4-methyl-5-ethoxycarbonyloxyoxazole 
• 65484-40-4 2-Isocyan-N-<(S)-1'-phenylethyl>propionsaeureamid 
• 302-72-7 rac-Ala-OH 
• 63348-62-9 N-Benzyl-2-isocyanpropionsaeureamid 
• 222845-01-4 N-formylalanine phenyl ester 
• 61167-49-5 N-formyl-L-alanine 4-nitrophenyl ester 
• 32221-83-3 (S)-N-formylalanine methyl ester 
• 69604-83-7 N-Formyl-L-alanine benzyl ester 
• 125698-55-7 C₁₄H₁₈N₂O₄ 
• 27646-78-2 (S)-(+)-2-(N-methylamino)propanol 

Relevant academic research and scientific papers

Application of polydopamine sulfamic acid-functionalized magnetic Fe3O4 nanoparticles (Fe3O4@PDA-SO3H) as a heterogeneous and recyclable nanocatalyst for the formylation of alcohols and amines under solvent-free conditions

Herein, formylation of structurally different amines and alcohols with ethyl formate was carried out in the presence of a catalytic proportion of sulfonic acid supported on polydopamine (PDA)-encapsulated Fe3O4 nanoparticles as a heterogeneous, recyclable, and greatly efficient catalyst; this method provided the corresponding N-formyl compounds in good to excellent yields under solvent-free conditions. The magnetically catalytic system was recovered, by-passing the time-consuming filtration operation using an external magnet device. This procedure also increases the purity of the product and promises economic and ecological advantages. Furthermore, the recovery and reuse of the catalyst was demonstrated five times without detectable loss in the activity.

Formyloxyacetoxyphenylmethane as an N-Formylating Reagent for Amines, Amino Acids, and Peptides

Formyloxyacetoxyphenylmethane is a stable, water-tolerant, N-formylating reagent for primary and secondary amines that can be used under solvent-free conditions at room temperature to prepare a range of N-formamides, N-formylanilines, N-formyl-α-amino acids, N-formylpeptides, and an isocyanide.

An aryne-based three-component access to α-aroylamino amides

Aryne chemistry has recently received widespread attention and isocyanides have been reported as efficient nucleophilic partners in a set of multicomponent transformations. In this study, we demonstrate that tertiary α-monosubstituted α-isocyanoacetamides are efficaciously coupled with water and benzyne to offer a direct and metal-free access to densely functionalized α-benzoylamino amides, without competing with the intramolecular cyclization to 5-aminooxazoles. Despite the formation of the aryl anion as a key intermediate, the reaction displays a stereoconservative course, allowing for the preparation of enantiomerically pure α-benzoylamino amides. Finally, the synthetic utility of the reported MCR was exemplified by the preparation of proglumide, a cholecystokinin antagonist.

Helical Polyisocyanopeptides as Lyotropic Liquid Crystals for Measuring Residual Dipolar Couplings

Residual dipolar couplings (RDC) emerged to be an important structural parameter for organic and biomolecules. Herein, a new helical polyisocyanopeptide (l,l-PIAF-OBn) that forms lyotropic liquid crystals (LLC) in CDCl3 is proposed as a novel weakly orienting medium for acquiring residual dipolar couplings (RDCs) of organic molecules. We demonstrate its application for the structural elucidation of strychnine and triptolide.

Enantioselective Synthesis of Quaternary Δ4- and Δ5-Dehydroprolines Based on a Two-Step Formal [3+2] Cycloaddition of α-Aryl and α-Alkyl Isocyano(thio)acetates with Vinyl Ketones

A divergent synthesis of optically active quaternary Δ4- and Δ5-dehydro prolines is developed based on the first catalytic enantioselective conjugate addition of α-substituted isocyano(thio)acetates to vinyl ketones that is general for both α-aryl and α-alkyl isocyano(thio)acetates. The new tetrasubstituted C?N stereocenter is formed without the need of any metal salt due to a bifunctional tertiary amine/squaramide catalyst, featuring a bulky polyaryl sidearm and an unusually short squaramide diamide H???H interatomic distance in the solid state.

ANTIFOULING AGENT FOR UNDERWATER ADHERING ORGANISMS HAVING AMINO ACID ISONITRILE SKELETON

PROBLEM TO BE SOLVED: To provide a novel antifouling agent for underwater adhering organisms having excellent characteristics compared with well-known antifouling agents. SOLUTION: An antifouling agent for underwater adhering organisms comprises a compound represented by formula (I) or salt thereof, or solvate thereof, as an active ingredient. COPYRIGHT: (C)2015,JPO&INPIT

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carbonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.

2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing metabolic disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used to the treatment of diabetes, lipid peroxidation, hypertriglyceridemia, metabolic disorders, free radical generated due to reactive oxygen and carhonyl groups, ionizing radiation, advanced glycation end products, kidney disease, renal complications and kidney stone disease.